(Q37630062)

21 August 2017

1 reference

title

HIV/hepatitis B virus co-infection: current challenges and new strategies (English)

1 reference

21 August 2017

0 references

1 reference

K Lacombe

1

1 reference

21 August 2017

J Bottero

2

1 reference

21 August 2017

M Lemoine

3

1 reference

21 August 2017

A Boyd

4

1 reference

21 August 2017

P M Girard

5

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Journal of Antimicrobial Chemotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

65

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

10-17

1 reference

Clinical implications of HIV and hepatitis B co-infection in Asia and Africa

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

HIV induces TRAIL sensitivity in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Natural killer-cell cytotoxicity in HIV-positive and HIV-negative patients with and without severe course of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Elevated serum levels of interferon- gamma -inducible protein-10 in patients coinfected with hepatitis C virus and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Hepatotoxicity and liver disease in the context of HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Current role of ultrasound for the management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Complete cure of HBV-HDV co-infection after 24weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

The HBV drug entecavir - effects on HIV-1 replication and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Telbivudine has activity against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Hepatitis B virus infection--natural history and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

HIV and hepatitis B co-infection in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

The global health burden of infection-associated cancers in the year 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP414

21 January 2018

Identifiers

DOI

10.1093/JAC/DKP414

1 reference

release_lyr2ugztb5acflpzk2fqtzye4q

21 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lyr2ugztb5acflpzk2fqtzye4q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference